Financière de Tubize SAの資本の返還
Financière de Tubize SAの資本の返還は何ですか。
Financière de Tubize SAの資本の返還は9.88%です。
資本の返還の定義は何ですか。
株主資本利益率は、株主資本の簿価との関係で事業の収益性の尺度です。これは、会計年度純利益を株主資本合計で除算することによって計算されます。
The return on equity (ROE) ROE is a measure of how well a company uses investments to generate earnings growth. ROE is used for comparing the performance of companies in the same industry. It indicated the management's ability to generate income from the equity available to it. ROEs of 15-20% are generally considered good. ROEs are also a factor in stock valuation, in association with other financial ratios. In general, stock prices are influenced by earnings per share (EPS), so that stock of a company with a 20% ROE will generally cost twice as much as one with a 10% ROE.
EURONEXTのセクタHealth Careにおける資本の返還の企業と比べるFinancière de Tubize SA
Financière de Tubize SAは何をしますか。
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Financière de Tubize SAと類似の資本の返還
- Genesys Internationalの資本の返還は9.87%です。
- Generix SAの資本の返還は9.87%です。
- ACCの資本の返還は9.87%です。
- Navigator Global Investmentsの資本の返還は9.87%です。
- Boiron SAの資本の返還は9.87%です。
- Boiron SAの資本の返還は9.87%です。
- Financière de Tubize SAの資本の返還は9.88%です。
- Sical Logisticsの資本の返還は9.88%です。
- B.L. Kashyap and Sonsの資本の返還は9.89%です。
- Xilam Animation SAの資本の返還は9.89%です。
- Xilam Animationの資本の返還は9.89%です。
- Gillanders Arbuthnot andの資本の返還は9.89%です。
- Sodifrance SAの資本の返還は9.89%です。